Addressing the Global Tragedy of Needless Pain: Rethinking the United Nations Single Convention on Narcotic Drugs

The lack of medical availability of effective pain medication is an enduring and expanding global health calamity. Despite important medical advances, pain remains severely under-treated worldwide, particularly in developing countries. This article contributes to the discussion of this global health crisis by considering international legal and institutional mechanisms to promote wider accessibility to critical narcotic drugs for pain relief

The Low-Velocity, Rapidly Fading Type Ia Supernova 2002es

SN 2002es is a peculiar subluminous Type Ia supernova (SN Ia) with a combination of observed characteristics never before seen in a SN Ia. At maximum light, SN 2002es shares spectroscopic properties with the underluminous SN 1991bg subclass of SNe Ia, but with substantially lower expansion velocities (~6000 km/s) more typical of the SN 2002cx subclass. Photometrically, SN 2002es differs from both SN 1991bg-like and SN 2002cx-like supernovae. Although at maximum light it is subluminous (M_B=-17.78 mag), SN 2002es has a relatively broad light curve (Dm15(B)=1.28 +/- 0.04 mag), making it a significant outlier in the light-curve width vs. luminosity relationship. We estimate a 56Ni mass of 0.17 +/- 0.05 M_sun synthesized in the explosion, relatively low for a SN Ia. One month after maximum light, we find an unexpected plummet in the bolometric luminosity. The late-time decay of the light curves is inconsistent with our estimated 56Ni mass, indicating that either the light curve was not completely powered by 56Ni decay or the ejecta became optically thin to gamma-rays within a month after maximum light. The host galaxy is classified as an S0 galaxy with little to no star formation, indicating the progenitor of SN 2002es is likely from an old stellar population. We also present a less extensive dataset for SN 1999bh, an object which shares similar observed properties. Both objects were found as part of the Lick Observatory Supernova Search, allowing us to estimate that these objects should account for ~2.5% of SNe Ia within a fixed volume. We find that current theoretical models are unable to explain the observed of characteristics of SN 2002es.Comment: 19 pages, 15 figures, Submitted to Ap

Constraints on a hadronic model for unidentified off-plane galactic gamma-ray sources

Recently the H.E.S.S. collaboration announced the detection of an unidentified gamma-ray source with an off-set from the galactic plane of 3.5 degrees: HESS J1507-622. If the distance of the object is larger than about one kpc it would be physically located outside the galactic disk. The density profile of the ISM perpendicular to the galactic plane, which acts as target material for hadronic gamma-ray production, drops quite fast with increasing distance. This fact places distance dependent constraints on the energetics and properties of off-plane gamma-ray sources like HESS J1507-622 if a hadronic origin of the gamma-ray emission is assumed. For the case of this source it is found that there seems to be no simple way to link this object to the remnant of a stellar explosions.Comment: 11 pages, 4 figures, accepted for publication in AdSp

Status of heavy quark physics from the lattice

In this short review, I present a summary of various methods used to simulate heavy quarks on the lattice. I mainly focus on effectives theories, and give some physical results.Comment: Talk given at QCD06, Montpellier July 06, 6 pages, 2 figures, espcrc2.st

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE - To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal. RESEARCH DESIGN AND METHODS - Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) in a trial evaluating add-on therapy to metformin with 50 mg vildagliptin bid. compared with glimepiride up to 6 mg q.d. in type 2 diabetes (baseline MC 7.3 +/- 0.6%). RESULTS - A1C and prandial glucose area under the curve (AUC)(0-2 h) were reduced similarly in both groups, whereas prandial insulin AUC(0-2 h) increased to a greater extent by glimepiride. Prandial glucagon AUC(0-2 h) (baseline 66.6 +/- 2.3 pmol . h(-1) . l(-1)) decreased by 3.4 +/- 1.6 pmol . h(-1) . l(-1) by vildagliptin (n = 137) and increased by 3.8 +/- 1.7 pmol . h(-1) . l(-1) by glimepiride (n = 121). The between-group difference was 7.3 +/- 2.1 pmol . h(-1) . l(-1) (P < 0.001). CONCLUSIONS - Vildagliptin therapy but not glimepiride improves postprandial a-cell function, which persists for at least 2 years